Roche, a Swiss pharmaceutical giant, announced its plan to acquire California-based biopharmaceutical company Poseida Therapeutics. The purchase price is set at $9 per share, valuing the total equity at $1 billion.
As part of the deal, shareholders will also receive a non-tradable Contingent Value Right (CVR) valued at $4 per share, potentially increasing the total transaction value to approximately $1.5 billion. Roche expects the acquisition to be finalized in the first quarter of 2025.
